AssisTek, based in Doylestown, PA, has announced its latest partnership with Philadelphia-based Strados Labs, which creates smart technology medical devices for respiratory illnesses.
assisTek's technology offerings include eCOA, ePRO, eConsent, BYOD modules.
"We are very excited to announce this partnership and are looking forward to working together with Strados to provide another way for clinicians and patients to gather novel information during their trials. By making the integration seamless into our current eDiary offerings, this paired technology will allow for better patient engagement and more efficient information gathering, with the ultimate goal of improved data for cures and treatment of these conditions," said Richard Gastineau, CEO of assisTek.
Strados Labs is a medical technology company developing smart sensor platforms that use machine learning and proprietary algorithms to detect and predict compounding conditions associated with serious, chronic respiratory diseases to improve the lives of patients globally.
"We are grateful and proud to solidify our partnership with assisTek. They have been a leader in integrating technology and data collection in clinical trials for over 20 years," said Strados Labs Director of Business Development, Shane Krauss. "We look forward to working with their experienced and knowledgeable team in clinical trials by helping them scale their digital therapeutics using our clinically validated measures for wheeze, cough, and other adventitious breath sounds, or CABS—which is something no other cleared device can measure."
The company developed a smart sensor platform for respiratory health, RESP, and recently received FDA Class II 510(k) clearance for home use. RESP was also granted a CE Mark late last year. The company is developing a pipeline algorithm to support and address other chronic diseases, as well as chronic disease management pathways. Strados will continue to target asthma, COPD and infectious respiratory diseases (COVID, RSV, and more)—with plans to add heart failure and pediatrics later this year.